Luminal breast cancer, defined by the expression of estrogen receptor (ER+) and the absence of human epidermal growth factor receptor 2 overexpression (HER2-), constitutes approximately 70% of newly diagnosed breast cancer cases.1 Despite advancements in outcomes in recent years, a recent pooled analysis by the Early Breast Cancer Trialists’ Collaborative Group revealed that the 10-year risk of distant recurrence after early breast cancer (EBC) was 7.3% for patients with no lymph node (LN) involvement, 14.7% for those with one to three positive LNs, and 28.5% for individuals with four or more positive LNs,2 underscoring the need for improved treatment options.